Abstract

To see the frequency of prostatic malignancy in patients presenting with clinically benign prostate. Study Design: Descriptive case series. Setting: Department of Urology at Peoples University of Medical and Health Sciences for Women / Hospital Nawabshah. Period: Fifteen Months, From October 2016 to December 2017. Materials and Methods: A total of 100 patients who presented with the clinically benign prostate in Urology OPD were enrolled. All concern data regarding Age, mode of presentation (lower urinary tract symptoms with IPSS score/ Acute retention of urine), comorbid, clinical examination findings, pre voided and post-void residual urine determination (on ultrasonography) were entered. The laboratory investigation includes complete blood count, urea, creatinine, random blood sugar (RBS), urine DR and CS, coagulation profile were performed before TURP.TURP performed under spinal anesthesia. After TURP the prostatic tissue chips were sent for histopathology as a routine. Data was analyzed through SPSS Version 20.0. Results: The average age of males was 71.38± 7.19 yrs. Most of the patients with (IPSS 20-35) BPH have lower urinary tract symptoms (both obstructive and irritative). DRE was done in all patients to estimate the size of the prostrate, it was varying from grade 1 enlarged n= 27(27%), grade 2 enlarged n= 36(36%), to grade 3 enlarged in n=37(37%). There were 3 (3%) cases reported to have prostate cancer, with findings confirmed by biopsy of TURP Specimen. There was no mortality seen in our study. The clinical presentation of patients, grades of enlargements on DRE and IPSS however, demonstrated no correlation. Conclusion: BPH is more common between 60-80yrs. When patient undergo TURP or open prostatectomy, every specimen should be sent for biopsy because prostate cancer is only confirmed by biopsy, so that prostate cancer is detected early Radiology & PSA values are supportive in their role but are not true diagnostic. Prostatic cancer is a significant morbid condition, so effective measures should be taken to detect prostatic cancer, so that patient can be properly treated according to the stage.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.